ibreakstock / iStockphoto.com
9 May 2018Americas
Pacific Biosciences and Oxford Nanopore settle patent claims
US-based Pacific Biosciences has entered into a five-year settlement agreement with Oxford Nanopore after the companies were locked in a legal battle.
Already registered?
Login to your account
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
Americas
19 October 2018 Amgen has invested £50 million ($66 million) in Oxford Nanopore Technologies, a UK company specialising in DNA/RNA sequencing technology.
Biotechnology
23 January 2019 The European Patent Office has revoked a patent held by a US biotechnology company, Pacific Biosciences, after its UK-based rival Oxford Nanopore Technologies challenged the validity of the patent.
Big Pharma
13 May 2021 The US Court of Appeals for the Federal Circuit has upheld a district court jury decision that found Pacific Biosciences’ DNA sequencing patents—which it had asserted against Oxford Nanopore Technologies—were invalid.
Editor's picks
Editor's picks
Americas
19 October 2018 Amgen has invested £50 million ($66 million) in Oxford Nanopore Technologies, a UK company specialising in DNA/RNA sequencing technology.
Biotechnology
23 January 2019 The European Patent Office has revoked a patent held by a US biotechnology company, Pacific Biosciences, after its UK-based rival Oxford Nanopore Technologies challenged the validity of the patent.
Big Pharma
13 May 2021 The US Court of Appeals for the Federal Circuit has upheld a district court jury decision that found Pacific Biosciences’ DNA sequencing patents—which it had asserted against Oxford Nanopore Technologies—were invalid.
Americas
19 October 2018 Amgen has invested £50 million ($66 million) in Oxford Nanopore Technologies, a UK company specialising in DNA/RNA sequencing technology.
Biotechnology
23 January 2019 The European Patent Office has revoked a patent held by a US biotechnology company, Pacific Biosciences, after its UK-based rival Oxford Nanopore Technologies challenged the validity of the patent.
Big Pharma
13 May 2021 The US Court of Appeals for the Federal Circuit has upheld a district court jury decision that found Pacific Biosciences’ DNA sequencing patents—which it had asserted against Oxford Nanopore Technologies—were invalid.